Pricing Log in Create free account
Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue
+51.9%
EPS
+73.9%
Free cash flow
−1,078.3%
Total debt
+4.04%

Quarter to September 2026, against a year earlier

132.13 2.33 +1.80%
Market cap
$6.8B
P/E
0.0×
Fwd P/E
−49.2×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Axsome Therapeutics, Inc. (AXSM) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Axsome Therapeutics, Inc. (AXSM) trades at a EV/Sales of 7.8×. Over the past ten years it has ranged from 0.0× (March 2023) to 26.5× (June 2023); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 13.9× 36.82%
FY2024 10.2× (16.42%)
FY2023 12.2× —
FY2022 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 11.0× (31.83%)
Jun 2026 16.1× 34.41%
Mar 2026 12.0× (14.03%)
Dec 2025 13.9× 33.00%
14 more quarters

Against its own ten years

Low 0.0× High 26.5×
Ten-year median 0.0×
Current reading's percentile 0

EV/Sales against peers

Company EV/Sales
BLTE Belite Bio, Inc. Sponsored ADR compare n/m
ABVX Abivax SA Sponsored ADR compare n/m
ORKA Oruka Therapeutics, Inc. compare n/m
IONS Ionis Pharmaceuticals, Inc. compare 7.0×
AXSM Axsome Therapeutics, Inc. 7.6×
MIRM Mirum Pharmaceuticals, Inc. compare 9.7×
RYTM Rhythm Pharmaceuticals, Inc. compare 24.3×
LGND Ligand Pharmaceuticals Incorporated compare 24.7×
PRAX Praxis Precision Medicines, Inc. compare 812×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on AXSM